In conclusion, this study elucidates the role of the IFN-γ/JAK/STAT1/CCL2/MMP13 pathway in exerting antitumor effects in pancreatic cancer by activating immune cells, which challenges the conventional understanding of CCL2 and MMP13 as promoters of tumor progression. The gene discussed is IFNG; the disease is familial pancreatic carcinoma.